CytomX Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview

CytomX Therapeutics

06/05/2023 03:03

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9. 
    * The South San Francisco California-based  company is
expected to
report  a 14.3% increase in revenue to $19.588 million from
$17.14 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for CytomX Therapeutics
Inc
is for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $2.13​, above​ its last closing price
of $1.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.17       -0.24      -0.43     Missed  -82.5
 Sep. 30 2022  -0.29       -0.31      -0.35     Missed  -14.5
 Jun. 30 2022  -0.36       -0.36      -0.37     Missed  -2.8​
 Mar. 31 2022  -0.38       -0.36      -0.37     Missed  -1.8
 ​​Dec.        -0.14       -0.28      -0.40     Missed  -41.7
 31 2021                                                
 Sep. 30 2021  -0.31       -0.31      -0.35     Missed  -12​
 Jun. 30 2021  -0.29       -0.32      -0.30     Beat    6
 Mar. 31 2021  -0.31       -0.35      -0.26     Beat    24.8
 This summary was machine generated May 6 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated